Business
CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary novel technologies to develop affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced today that it has completed with full payment the acquisition of the allogeneic gamma delta T cell technology
About this update from Cytomed Therapeutics Limited
[{"type":"image","alt":"CYTOMED THERAPEUTICS LIMITED","displaySize":"","headline":null,"caption":"CYTOMED THERAPEUTICS LIMITED","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":139,"url":"https://media.zenfs.com/en/globenewswire.com/a5ea200fbc7d9222864b186d49fef81e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kZfTE6ya73voiEtLPclhmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a5ea200fbc7d9222864b186d49fef81e","width":300,"height":139}},"lazy":false},{"type":"text","content":"SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary novel technologies to develop affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced today that it has completed with full payment the acquisition of the allogeneic gamma delta T cell technology (termed “TCB-002”) of TC BioPharm Limited (“TCBL”), a subsidiary of TC BioPharm (Holdings) PLC (OTC:TCBPY). This follows CytoMed’s announcement on October 14, 2025 regarding its proposed acquisition of potentially synergistic assets from TCBL.","length":744,"tagName":"p"},{"type":"text","content":"TCB-002 will complement CytoMed’s strategy to establish a next-generation non-viral allogeneic gamma delta T cell immunotherapy platform to treat cancer and autoimmune diseases. The acquired technology for TCB-002 has previously completed a Phase I clinical trial in Europe and was granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of Acute Myeloid Leukemia.","length":399,"tagName":"p"},{"type":"text","content":"CytoMed is currently in advanced collaborative discussions with prospective partners to further enhance and repurpose this technology for cancer treatment applications in China and India. This prospective collaboration seeks, amongst other things, to jointly develop and commercialize a new method of manufacturing donor-derived unmodified allogeneic gamma delta T cells. This method does not require the use of living cell. Instead, it uses cytokine that can be manufactured in China at lower cost. Because China currently has strict rules governing the import and e...